Brought to you by 
Sequenom buys Gemini Genomics for $224mm in stock
19 Feb 2002
Executive Summary
Sequenom (gene analysis) is buying Gemini Genomics (clinical genomics) in an all-stock deal that values Gemini at $224mm, a premium of (pr)26% based on its most recent trading price prior to the announcement. The companies expect the transaction to close in the third quarter.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sequenom buys Gemini Genomics for $224mm in stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice